Skip to content

Gyre Therapeutics, Inc. GYRE Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin95.1%-0.3pp95.4%-0.1pp95.5%-0.4pp95.9%-0.3pp96.2%-0.1pp
Operating margin-0.1%-10.0pp9.9%-1.4pp11.2%+2.1pp9.1%-1.2pp10.3%-5.0pp
Returns
Return on invested capital-0.1%-12.9pp12.8%
Efficiency
Asset turnover0.8×0.0×0.8×0.0×0.8×0.0×0.7×-0.1×0.8×-0.1×
Liquidity
Current ratio4.6×-1.0×5.6×-0.6×6.2×+0.8×5.4×+1.8×3.6×+0.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA-14.8×-12.2×-2.6×+0.2×-2.7×
Per Share
Book value per share$1.11+7.9%$1.03+4.8%$0.98+9.4%$0.90+34.1%$0.67+7.9%
Valuation
Market capitalization$694.58M-4.7%$680.11M+0.4%$677.57M-1.8%$689.9M-4.5%$722.69M-30.4%
Price / sales5.9×-1.3×5.8×-0.5×6.3×-0.4×6.8×-0.4×7.2×-2.6×
Price / book6.9×-3.8×6.4×-0.2×6.6×-0.8×7.5×-3.1×10.6×-5.8×
EV / EBITDA265.6×+206×46.1×+1.5×44.6×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Gyre Therapeutics, Inc.'s profit margins?
Gyre Therapeutics, Inc. (GYRE) runs a 95.1% gross margin and a -0.1% operating margin, with a 6.3% net margin.
Where do Gyre Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.